1.
Pediatr Blood Cancer
; 49(5): 736-9, 2007 Oct 15.
Artículo
en Inglés
| MEDLINE
| ID: mdl-16317734
RESUMEN
We report our experience with a small child with severe factor VII deficiency and a history of frequent and spontaneous life-threatening hemorrhage. The patient has received several years of successful prophylactic treatment with an every 3-day infusion program in which she receives recombinant activated factor VII (rVIIa) using multiple doses from a single reconstituted vial over a 72-hr period. Comparison is made to prophylactic treatment in this same patient using plasma-derived factor VII (PDVII) using a prothrombin complex concentrate (PCC).